Influence of cardiac biomarkers on predicting significant coronary artery disease in hypertrophic cardiomyopathy patients.
Cardiac biomarkers
Coronary artery disease
High sensivite Troponin-T
Hypertrophic cardiomyopathy
NT-proBNP
Journal
Heart and vessels
ISSN: 1615-2573
Titre abrégé: Heart Vessels
Pays: Japan
ID NLM: 8511258
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
27
04
2023
accepted:
29
06
2023
medline:
23
10
2023
pubmed:
7
7
2023
entrez:
6
7
2023
Statut:
ppublish
Résumé
In this study, our aim was to investigate the role of cardiac biomarkers in predicting the presence of significant coronary artery disease in hypertrophic cardiomyopathy (HCM) patients. The study population was composed of hypertrophic cardiomyopathy patients who underwent coronary angiography at a single center between June 2021 and March 2023, and whose cardiac biomarkers were evaluated before the procedure. HCM patients were screened retrospectively. Significant CAD was defined as > 50% stenosis of the left main coronary artery or > 70% stenosis in a major coronary vessel. Demographic, echocardiographic and cardiac biomarker values were compared between the two groups. A total of 123 patients were evaluated. Significant CAD was detected in 39 (31.7%) patients. Patients with significant CAD had higher CK-MB values than those without CAD [2.8 (2.1-4.0) vs. 3.4 (2.8-4.6), p = 0.036], and a higher level of high-sensitivity troponin T (hs-TnT) than those without CAD (24 vs. 17.8, p = 0.022). the NT-proBNP/hs-TnT ratio was found to be significantly lower in patients with CAD than in those with CAD (31.4 vs. 21.4, p = 0.019). In multivariate anaylsis, NT-proBNP/hs-TnT was determined as an independent predictor for significant CAD. In ROC analysis, NT-proBNP/hs-TnT ratio lower than the cut-off value of 30.7 could detect the presence of significant CAD with 76.9% sensitivity and 53.6% specificity (AUC: 0.632, 95% CI: 0.528-0.736, p = 0.019). To sum up, we suggest that cardiac biomarkers were valuable and simple parameters in terms of significant CAD in HCM patients.
Sections du résumé
BACKGROUND
BACKGROUND
In this study, our aim was to investigate the role of cardiac biomarkers in predicting the presence of significant coronary artery disease in hypertrophic cardiomyopathy (HCM) patients.
METHODS
METHODS
The study population was composed of hypertrophic cardiomyopathy patients who underwent coronary angiography at a single center between June 2021 and March 2023, and whose cardiac biomarkers were evaluated before the procedure. HCM patients were screened retrospectively. Significant CAD was defined as > 50% stenosis of the left main coronary artery or > 70% stenosis in a major coronary vessel. Demographic, echocardiographic and cardiac biomarker values were compared between the two groups.
RESULTS
RESULTS
A total of 123 patients were evaluated. Significant CAD was detected in 39 (31.7%) patients. Patients with significant CAD had higher CK-MB values than those without CAD [2.8 (2.1-4.0) vs. 3.4 (2.8-4.6), p = 0.036], and a higher level of high-sensitivity troponin T (hs-TnT) than those without CAD (24 vs. 17.8, p = 0.022). the NT-proBNP/hs-TnT ratio was found to be significantly lower in patients with CAD than in those with CAD (31.4 vs. 21.4, p = 0.019). In multivariate anaylsis, NT-proBNP/hs-TnT was determined as an independent predictor for significant CAD. In ROC analysis, NT-proBNP/hs-TnT ratio lower than the cut-off value of 30.7 could detect the presence of significant CAD with 76.9% sensitivity and 53.6% specificity (AUC: 0.632, 95% CI: 0.528-0.736, p = 0.019).
CONCLUSION
CONCLUSIONS
To sum up, we suggest that cardiac biomarkers were valuable and simple parameters in terms of significant CAD in HCM patients.
Identifiants
pubmed: 37414867
doi: 10.1007/s00380-023-02287-0
pii: 10.1007/s00380-023-02287-0
doi:
Substances chimiques
Biomarkers
0
Troponin T
0
Peptide Fragments
0
Natriuretic Peptide, Brain
114471-18-0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1329-1336Informations de copyright
© 2023. Springer Nature Japan KK, part of Springer Nature.
Références
Sorajja P, Ommen SR, Nishimura RA, Gersh BJ, Berger PB, Tajik AJ (2003) Adverse prognosis of patients with hypertrophic cardiomyopathy who have epicardial coronary artery disease. Circulation 108:2342–2348
doi: 10.1161/01.CIR.0000097110.55312.BF
pubmed: 14581405
Elliott PM, Kaski JC, Prasad K, Seo H, Slade AK, Goldman JH, McKenna WJ (1996) Chest pain during daily life in patients with hypertrophic cardiomyopathy: an ambulatory electrocardiographic study. Eur Heart J 17:1056–1064
doi: 10.1093/oxfordjournals.eurheartj.a015002
pubmed: 8809524
van der Velde N, Huurman R, Yamasaki Y, Kardys I, Galema TW, Budde RP, Zijlstra F, Krestin GP, Schinkel AF, Michels M, Hirsch A (2020) Frequency and significance of coronary artery disease and myocardial bridging in patients with hypertrophic cardiomyopathy. Am J Cardiol 125:1404–1412
doi: 10.1016/j.amjcard.2020.02.002
pubmed: 32111340
Walston A, Behar VS (1976) Spectrum of coronary artery disease in idiopathic hypertrophic subaortic stenosis. Am J Cardiol 38:12–16
doi: 10.1016/0002-9149(76)90056-4
pubmed: 945682
Lazzeroni E, Rolli A, Aurier E, Botti G (1992) Clinical significance of coronary artery disease in hypertrophic cardiomyopathy. Am J Cardiol 70:499–501
doi: 10.1016/0002-9149(92)91197-C
pubmed: 1642188
Puwanant S, Trongtorsak A, Wanlapakorn C, Songsirisuk N, Ariyachaipanich A, Boonyaratavej S (2021) Acute coronary syndrome with non-obstructive coronary arteries (ACS-NOCA) in patients with hypertrophic cardiomyopathy. BMC Cardiovasc Disord 21:556
doi: 10.1186/s12872-021-02373-z
pubmed: 34798824
pmcid: 8603536
Jacob R, Khan M (2018) Cardiac biomarkers: what is and what can be. Indian J Cardiovasc Dis Women WINCARS 3:240–244
doi: 10.1055/s-0039-1679104
pubmed: 31934672
pmcid: 6957084
Nadar SK, Shaikh MM (2019) Biomarkers in routine heart failure clinical care. Card Fail Rev 5:50–56
doi: 10.15420/cfr.2018.27.2
pubmed: 30847246
pmcid: 6396063
Matthia EL, Setteducato ML, Elzeneini M, Vernace N, Salerno M, Kramer CM, Keeley EC (2022) Circulating biomarkers in hypertrophic cardiomyopathy. J Am Heart Assoc 11:e027618
doi: 10.1161/JAHA.122.027618
pubmed: 36382968
pmcid: 9851432
Topf A, Mirna M, Paar V, Motloch LJ, Bacher N, Franz M, Hoppe UC, Kretzschmar D, Lichtenauer M (2022) Differential diagnosis between Takotsubo syndrome and acute coronary syndrome—a prospective analysis of novel cardiovascular biomarkers for a more selective triage. J Clin Med 11:2974
doi: 10.3390/jcm11112974
pubmed: 35683362
pmcid: 9180967
Fröhlich GM, Schoch B, Schmid F, Keller P, Sudano I, Lüscher TF, Noll G, Ruschitzka F, Enseleit F (2012) Takotsubo cardiomyopathy has a unique cardiac biomarker profile: NT-proBNP/myoglobin and NT-proBNP/troponin T ratios for the differential diagnosis of acute coronary syndromes and stress induced cardiomyopathy. Int J Cardiol 154:328–332
doi: 10.1016/j.ijcard.2011.09.077
pubmed: 22044675
Cokkinos DV, Krajcer Z, Leachman RD (1985) Hypertrophic cardiomyopathy and associated coronary artery disease. Tex Heart Inst J 12:147–151
pubmed: 15227023
pmcid: 341827
Shin YJ, Lee JH, Yoo JY, Kim JA, Jeon Y, Yoon YE, Chun EJ (2019) Clinical significance of evaluating coronary atherosclerosis in adult patients with hypertrophic cardiomyopathy who have chest pain. Eur Radiol 29:4593–4602
doi: 10.1007/s00330-018-5951-8
pubmed: 30796567
Harjai KJ, Cheirif J, Murgo JP (1996) Ischemia and atherosclerotic coronary artery disease in patients with hypertrophic cardiomyopathy: a review of incidence, pathophysiological mechanisms, clinical implications and management strategies. Coron Artery Dis 7:183–187
pubmed: 8827402
Khan S, Rasool ST (2021) Current use of cardiac biomarkers in various heart conditions. Endocr Metab Immune Disord Drug Targets 21:980–993
doi: 10.2174/1871530320999200831171748
pubmed: 32867665
Cambronero F, Marín F, Roldán V, Hernández-Romero D, Valdés M, Lip GYH (2009) Biomarkers of pathophysiology in hypertrophic cardiomyopathy: implications for clinical management and prognosis. Eur Heart J 30:139–151
doi: 10.1093/eurheartj/ehn538
pubmed: 19136482
Ho JE, Shi L, Day SM, Colan SD, Russell MW, Towbin JA, Sherrid MV, Canter CE, Jefferies JL, Murphy A, Taylor M, Mestroni L, Cirino AL, Sleeper LA, Jarolim P, Lopez B, Gonzalez A, Diez J, Orav EJ, Ho CY (2017) Biomarkers of cardiovascular stress and fibrosis in preclinical hypertrophic cardiomyopathy. Open Heart 4:e000615
doi: 10.1136/openhrt-2017-000615
pubmed: 29177058
pmcid: 5687543
Rusnak J, Fastner C, Behnes M, Mashayekhi K, Borggrefe M, Akin I (2017) Biomarkers in stable coronary artery disease. Curr Pharm Biotechnol 18:456–471
doi: 10.2174/1389201018666170630120805
pubmed: 28669333
McCarthy CP, McEvoy JW, Januzzi JL (2018) Biomarkers in stable coronary artery disease. Am Heart J 196:82–96
doi: 10.1016/j.ahj.2017.10.016
pubmed: 29421018
Daněk J, Hnátek T, Malý M, Táborský M, Běláček J, Škvaril J, Pospíšilová L, Černohous M, Sedloň P, Hajšl M, Zavoral M (2017) Troponin levels in patients with stable CAD. Cor Vasa 59:e229-234
doi: 10.1016/j.crvasa.2016.12.001
Tveit SH, Myhre PL, Hanssen TA, Forsdahl SH, Iqbal A, Omland T, Schirmer H (2022) Cardiac troponin I and T for ruling out coronary artery disease in suspected chronic coronary syndrome. Sci Rep 12:945
doi: 10.1038/s41598-022-04850-7
pubmed: 35042885
pmcid: 8766564
Kim DH, Lee SH, Kim SC, Kim T, Kang C, Jeong JH, Park YJ, Lim D, Lee SB (2019) The ratio of N-terminal pro-B-type natriuretic peptide to troponin I for differentiating acute coronary syndrome. Am J Emerg Med 37:1013–1019
doi: 10.1016/j.ajem.2018.08.035
pubmed: 30122508